Investigating how a specific protein affects metastatic prostate cancer
Official title: Determine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10879288 · Data updated 2026-11-12
This study is looking at a protein called ASH1L to see how it affects the spread of metastatic prostate cancer, with the hope of finding new ways to treat patients facing this challenge.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $537,699 |
| NIH project number | 1R01CA278889-01A1 |
| Project ID | NIH-10879288 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic prostate cancer who may benefit from novel therapeutic approaches.
✕Less likely to help
Patients with localized prostate cancer or those who have not developed metastatic disease may not benefit from this research.
What this research studies
This research focuses on understanding the role of the ASH1L protein in the progression of metastatic prostate cancer. By examining how ASH1L influences the tumor immune microenvironment, the study aims to uncover new mechanisms that contribute to cancer spread. Using advanced techniques like genetically engineered mouse models and single-cell transcriptomics, researchers will explore how ASH1L may serve as a potential therapeutic target. This could lead to the development of more effective treatments for patients with metastatic disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target the mechanisms of metastasis in prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic factors in cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Zhao, Di — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhao, Di
Related research
Other NIH-funded projects on the same topics.
-
Combination immunotherapy with radioligand therapy for metastatic prostate cancer
A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.
-
Understanding what drives lethal metastatic prostate cancer in men
This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.
-
Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer
A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.
-
ASH1L’s role in metastatic prostate cancer and its immune environment
Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.
-
Molecular drivers of lineage changes and new therapies for metastatic prostate cancer
A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.
-
How gut bacteria may affect prostate cancer therapy and resistance
A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.